Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Kasr El-Aini, Cairo, 11562, Egypt.
Department of Pharmaceutics, Faculty of Pharmacy, Ahram Canadian University, Giza, Egypt.
AAPS PharmSciTech. 2019 Jul 22;20(7):258. doi: 10.1208/s12249-019-1472-2.
Febuxostat suffers from relatively low bioavailability owing to the poor drug solubility and hepatic first-pass effect. This study aimed to prepare highly drug-loaded self-nanoemulsifying self-nanosuspension systems (SNESNS). SNESNS were designed to improve febuxostat's oral bioavailability by enhancing its solubility. Different oil and surfactant/co-surfactant mixtures were used for the preparation of SNESNS. The prepared SNESNS were estimated for their particle size, in vitro drug release and transmission electron microscopy (TEM). Results revealed that the oil mixture of Capryol™ 90:Miglyol 812 (1:1 w/w) with surfactant/co-surfactant mixture of Cremophor RH 40/Transcutol HP loaded with drug in 4-fold greater concentration than its saturated solubility resulted in the formation of SNESNS by dilution under the effect of magnetic stirring. SNESNS were freeze-dried using trehalose as a cryoprotectant. TEM images and the bimodal particle size curve confirmed the formation of the biphasic nanosystems after dilution (nanoemulsion and nanosuspension). Higher C and AUC values compared to those of the market product Feburic tablets confirmed the success of the SNESNS as a promising carrier for drugs suffering from poor water solubility like febuxostat.
非布司他由于药物溶解度差和肝脏首过效应,生物利用度相对较低。本研究旨在制备高载药量的自纳米乳自纳米混悬剂系统(SNESNS)。SNESNS 的设计目的是通过提高其溶解度来提高非布司他的口服生物利用度。不同的油和表面活性剂/共表面活性剂混合物被用于制备 SNESNS。对所制备的 SNESNS 进行了粒径、体外药物释放和透射电子显微镜(TEM)的评估。结果表明,Capryol™90:Miglyol 812(1:1w/w)油混合物与 Cremophor RH 40/Transcutol HP 表面活性剂/共表面活性剂混合物的载药量是其饱和溶解度的 4 倍,在磁场搅拌的作用下通过稀释形成 SNESNS。采用海藻糖作为冷冻保护剂对 SNESNS 进行冷冻干燥。TEM 图像和双峰粒径曲线证实了稀释后(纳米乳和纳米混悬剂)形成双相纳米系统。与市售产品 Feburic 片剂相比,C 和 AUC 值更高,证实了 SNESNS 作为一种有前途的载体,可用于改善像非布司他这样水溶性差的药物。